

November 08, 2017

TAKE/BSE/2017-18

The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai - 400001

TECHNOLOGY ANALYTICS KNOWLEDGE ENTERPRISE

TAKE/NSE/2017-18

The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400051

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on Wednesday, November 08, 2017
Ref: NSE Scrip Code: 523890 & BSE Scrip Code: TAKE

We wish to inform you that the Board of Directors of the Company, in its meeting held on Wednesday, November 08, 2017, approved the following:

1. The Unaudited Financial Results of the Company [stand-alone] and the Group [Company and its subsidiaries- Consolidated] for the quarter (Q2) and Half Year (H1) ended September 30, 2017, as recommended by the Audit Committee. The copy of the same in the prescribed format in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 along with the Limited Review Report by the Statutory Auditor is enclosed herewith.
2. Declaration of First Interim Dividend @ INR 0.30/- (30%) per Equity Share (Face value INR 1.00/- each). The Interim Dividend shall be disbursed on or before December 07, 2017 and the Record Date for payment of Interim Dividend is fixed at November 16, 2017.

The meeting of Board of Directors of the Company commenced at 10:30 a.m. and concluded at 3:15 p.m.

Please take note of the same.

Thanking you,

Yours sincerely,
For TAKE Solutions Limited


Avaneesh
Company Secretary



Encl: A/a:

TAKE Solutions sustains growth momentum with Q2 FY18 profits of INR 374 Mn

The company reported an 18.7% y-o-y growth in profits

Figures in INR million unless mentioned	Q2 FY18	Q2 FY17	Y-o-Y change (%)
Revenue	3,709	3,283	13.0
EBITDA	700	652	7.4
Net Profit	374	315	18.7
Diluted Earnings Per Share (INR)	2.83	2.16	31.0

Chennai, November 8th 2017 - TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a globally recognized domain intensive services provider in Life Sciences and Supply Chain Management, today announced its financial results for Q2 FY18. The Company carried forward the momentum witnessed in Q1 FY18, reporting strong Q2 revenue and profit figures of **INR 3,709 Mn.** and **INR 374 Mn.** respectively as it progressed along its 5-year transformational scale up journey to emerge as a significantly larger enterprise.

Last quarter, the Company announced the consolidation of its specialized Life Sciences brands **Navitas** (technology-led Life Sciences services provider across Clinical, Regulatory and Safety), **Ecron Acunova** (CRO with Clinical and BA/BE capabilities) and **Intelent** (Big Data Analytics expert) as **Navitas Life Sciences**, an end-to-end provider of transformative services offering a full-service coverage of the Pharma and Biotech R&D market. The success of this go-to-market strategy stands validated by the **17.96% y-o-y growth in Life Sciences revenue.**

In recognition of its internal processes, structure and governance best practices, TAKE was bestowed with the **Golden Peacock Awards for Excellence in Corporate Governance** by the prestigious Institute of Directors at their international convention of global leaders at London.

Mr. Srinivasan HR, Vice Chairman and Managing Director, TAKE Solutions said, “The successful integration of the complimentary, niche capabilities of our legacy brands as Navitas Life Sciences continues to register tremendously positive business impact as witnessed by our consistently strong performances and prestigious industry recognitions. We are in a very promising position to penetrate new markets and further capitalize on global opportunities as we move closer to achieving the growth target envisioned in our transformational scale-up initiative.”

About TAKE Solutions:

TAKE Solutions delivers domain-intensive services in Life Sciences and Supply Chain Management.

In the fast-growing Life Sciences space, TAKE offers clients a unique combination of a full-service CRO backed by industry insights and technology expertise. Our range of services span from clinical trials to regulatory submissions to post-marketing safety, all backed by insights

derived through our proprietary industry networks. With a team of leading Life Sciences experts, best-in-class systems and processes, and bespoke, industry-specific technology and analytics, TAKE delivers outcomes for clients, including 9 of the top 10 global pharmaceutical companies.

In Supply Chain Management, TAKE focuses on high-margin niches in engineering, mobility and collaboration. Our IP-led approach enables our clients to automate supply chain processes, track, trace & control at item level, extend mobility, mandate supplier compliance, and streamline material & shipment movement, and thus optimize their processes.

With operations spread across North America, Europe, Asia, and South America, TAKE is a Public Company, listed in India on the Bombay Stock Exchange and the National Stock Exchange. Led by a team of industry stalwarts and domain experts, TAKE has been growing steadily with FY17 revenues touching INR 13,520 Mn, a 29% increase year-on-year.

For more information, please visit www.takesolutions.com

Contacts::

Samhita Suresh, TAKE Solutions, +91 44 66110700, samhita.suresh@takesolutions.com

Jayeeta Chowdhury, 20:20 MSL, +91 9962750769, jayeeta.chowdhury@2020msl.com